Stock listing
A2PEAB Stock Price, News, Filings & Events — Celldex Therapeutics, Inc.
Selected listing: A2PEAB · LSX · EUR · DE
This page tracks Celldex Therapeutics, Inc.'s A2PEAB:LSX listing on LSX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2PEAB:LSX. A2PEAB:LSX is the stock-level entry point for investors researching Celldex Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Celldex Therapeutics, Inc. (Ticker: CLDX) is a public company based in the United States with a market capitalization of approximately $2.77 billion. The company focuses on developing innovative therapies for cancer and other serious diseases. Celldex is committed to advancing its pipeline of products to improve patient outcomes.
- Ticker
- A2PEAB:LSX
- Asset type
- Stock
- Market cap
- $2.90B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- LSX
- Currency
- EUR
Celldex Therapeutics, Inc. A2PEAB:LSX stock context
This page tracks Celldex Therapeutics, Inc.'s A2PEAB:LSX listing on LSX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2PEAB:LSX. A2PEAB:LSX is the stock-level entry point for investors researching Celldex Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Celldex Therapeutics, Inc. (Ticker: CLDX) is a public company based in the United States with a market capitalization of approximately $2.77 billion. The company focuses on developing innovative therapies for cancer and other serious diseases. Celldex is committed to advancing its pipeline of products to improve patient outcomes.
Latest news from Celldex Therapeutics, Inc.
Celldex Reports Second Quarter Financial Results and Provides Corporate Update
August 6, 2026
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
July 21, 2026
Celldex Announces Planned Transition of Chief Financial Officer
July 15, 2026
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at ...
June 14, 2026
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Cl...
June 14, 2026
Celldex Therapeutics, Inc. earnings calls
Research Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for A2PEAB:LSX.
Celldex Therapeutics, Inc. company profile
View the public company page for Celldex Therapeutics, Inc. on 6ix.
Celldex Therapeutics, Inc. news
Read company news and market updates connected to Celldex Therapeutics, Inc..
Celldex Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Celldex Therapeutics, Inc..
Alternate listings
CLDX:NASDAQ
US · USD
Alternate listing for Celldex Therapeutics, Inc.; the primary context on this page is A2PEAB:LSX.
TCE2:GETTEX
DE · EUR
Alternate listing for Celldex Therapeutics, Inc.; the primary context on this page is A2PEAB:LSX.
A2PEAB:LS
DE · EUR
Alternate listing for Celldex Therapeutics, Inc.; the primary context on this page is A2PEAB:LSX.
TCE2:TRADEGATE
DE · EUR
Alternate listing for Celldex Therapeutics, Inc.; the primary context on this page is A2PEAB:LSX.
CLDX:BOATS
US · USD
Alternate listing for Celldex Therapeutics, Inc.; the primary context on this page is A2PEAB:LSX.
TCE1:BX
CH · CHF
Alternate listing for Celldex Therapeutics, Inc.; the primary context on this page is A2PEAB:LSX.
TCE2:DUS
DE · EUR
Alternate listing for Celldex Therapeutics, Inc.; the primary context on this page is A2PEAB:LSX.
TCE2:FWB
DE · EUR
Alternate listing for Celldex Therapeutics, Inc.; the primary context on this page is A2PEAB:LSX.
TCE2:MUN
DE · EUR
Alternate listing for Celldex Therapeutics, Inc.; the primary context on this page is A2PEAB:LSX.
TCE2:SWB
DE · EUR
Alternate listing for Celldex Therapeutics, Inc.; the primary context on this page is A2PEAB:LSX.